Rest-of-world markets offer good opportunities for rare disease companies to expand their sales potential beyond what U.S. & E.U. markets offer, and the requirements for market entry should be considered at a high level early on.
As the COVID-19 pandemic rages on, the effects of the virus are being felt not only by the global populace, but by the various sectors of the health care industry and those that support them.
Sickle cell disease is a group of inherited disorders that affects hemoglobin, the oxygen-carrying protein in red blood cells (RBCs), and causes these cells to distort in shape at low oxygen levels. This condition affects 1 in 500 Americans of African descent and 1 in 1,000-1,400 of Hispanic descent, as well as millions...
How cells sense and adapt to oxygen availability plays an important role in anemia, cancer, stroke, infection, wound healing, and myocardial infarction.
Challenges and opportunities in the field of spinal muscular atrophy, including how new disease-modifying therapies are likely to change SMA’s course over time.
ICER is expected to update the assessment framework underpinning its evidence reports on new drugs and health care interventions at the end of this year. What changes are likely to be made?